Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

In a phase 1 trial, idelalisib (GS-1101, CAL-101), a selective inhibitor of the lipid kinase PI3Kδ, was evaluated in 54 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) with adverse characteristics including bulky lymphadenopathy (80%), extensive prior therapy (median 5 [range 2-...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Brown, Jennifer R., Byrd, John C., Coutre, Steven E., Benson, Don M., Flinn, Ian W., Wagner-Johnston, Nina D., Spurgeon, Stephen E., Kahl, Brad S., Bello, Celeste, Webb, Heather K., Johnson, Dave M., Peterman, Sissy, Li, Daniel, Jahn, Thomas M., Lannutti, Brian J., Ulrich, Roger G., Yu, Albert S., Miller, Langdon L., Furman, Richard R.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2014
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123414/
https://ncbi.nlm.nih.gov/pubmed/24615777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-11-535047
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky